ABVX: ABIVAX Company Value to Net Income
Stable demand for IBD therapy promises ABIVAX (ABVX) multi-year excess profits, which is confirmed by the P/E multiple level, where the current status is -15.50. The success of the biopharmaceutical business relies on clinical test results and regulatory approvals. Meanwhile, the operating model is protected by its humanitarian status, minimizing any geopolitical risks and sanctions pressure.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_ABVX_-_ABIVAX_-_PE-Multiple "ABVX: Abivax SA Business Payback Period 02/21/2024 - 11/13/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for ABIVAX (ABVX)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
- earnings and market multiples details:
ABVX - Net Profit|Expected Profit ABIVAX|ABVX - P/E Multiple|Market Cap to Projected Earnings Abivax S.A.|ABVX - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Abivax SA|ABVX - Operating profit EBITDA|Net earnings per share (EPS TTM) Abivax|ABVX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months abivax.com|ABVX - Earnings growth in current year|Earnings growth forecast for next year ABIVAX
Comprehensive company analysis:Abivax SA ABVX
The stability of ABIVAX (ABVX) depends on the successful market launch of obefeximod for the therapy of intestinal inflammation. By analyzing the P/E ratio, an investor determines the premium for future earnings, where an increasing multiple reflects market confidence in the drug's commercialization, while an excessive surge signals an overpayment for the asset and a decrease in potential investment returns.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ADMA (ADMA Biologics Inc) - Company Value to Net Income|P/E Multiple PTGX (Protagonist Therapeutics Inc)|Business Payback Period Immunovant Therapeutics (IMVT)|KNSA - Price to Earnings Ratio|grifols.com (GRFS) - Price to Earnings Ratio|Adaptive Biotechnologies Corporation (ADPT) - Price to Earnings Ratio|Price to Earnings Ratio Celldex Therapeutics Inc|Price to Earnings Ratio AUPH|P/E Multiple BioCryst Corp|Price to Earnings Ratio Vera Therapeutics, Inc. (VERA)|dianthustx.com - Price to Earnings Multiple|P/E Multiple PHVS (Pharvaris)|AbCellera Corp (ABCL) - Market Cap to Earnings|Tourmaline Corp - P/E Multiple|PGEN - P/E Multiple|PHAR: P/E Multiple|NKTR (nektar.com) - Price to Earnings Ratio|UPB (Upstream Bio) - P/E Multiple|Zenas Bio (ZBIO) - Business Payback Period|Price to Earnings Ratio IMNM (Immunome Corp)|Price to Earnings Ratio GOSS (Gossamer Bio Corp.)|P/E Multiple KALV (KalVista Pharmaceuticals)|P/E Multiple septerna.com SEPN|PVLA: Price to Earnings Ratio|SVRA (Savara Inc) - Price to Earnings Multiple|RIGL: P/E Multiple|AnaptysBio Inc. (ANAB) - P/E Multiple|ATXS (Astria Therapeutics) - P/E Multiple|Price to Earnings Ratio ENGN|Price to Earnings Ratio RAPT (RAPT Therapeutics)|Price to Earnings Ratio JBIO (aerovatetx.com)|Aclaris - Price to Earnings Ratio|KYTX: Price to Earnings Multiple|TLSA - Price to Earnings Ratio|Market Cap to Net Income CABA|VTYX: P/E Multiple|Theratechnologies, Inc. - Company Value to Net Income|AVTX (Avalo Therapeutics Inc.) - P/E Multiple|P/E Multiple Eledon Pharmaceuticals, Inc|Price to Earnings Ratio Agenus (AGEN)|CLYM (climbbio.com) - Company Value to Net Income|Price to Earnings Ratio Zura Bio ZURA|ATYR - Price to Earnings Ratio|Adagene Corp - P/E Multiple|IMA - P/E Multiple|STTK (shattucklabs.com) - Price to Earnings Ratio|Equillium - Company Value to Net Income|CNTB (Connect Biopharma Holdings) - P/E Multiple|Immunic Inc (IMUX) - Business Payback Period|Price to Earnings Ratio Atara Biotherapeutics (ATRA)|Price to Earnings Ratio inflarx.de IFRX|Price to Earnings Ratio X4 Pharmaceuticals XFOR|ACET - Price to Earnings Ratio|CELU: Price to Earnings Ratio|INMB - P/E Multiple|Barinthus Bio (BRNS) - Price to Earnings Ratio|Price to Earnings Multiple KZR|SABS (SAB Biotherapeutics) - P/E Multiple|Market Cap to Earnings akaritx.com AKTX|P/E Multiple ENLV|P/E Multiple q32bio.com (QTTB)|P/E Multiple GOVX (GeoVax Labs Inc)|Edesa Biotech Corp - Price to Earnings Ratio|iBio, Inc. - P/E Multiple|Business Payback Period Carisma Therapeutics CARM|XTLB (XTL Biopharmaceuticals Ltd.) - Price to Earnings Ratio|BOLT (Bolt Biotherapeutics, Inc.) - Price to Earnings Ratio|HCWB (HCW Biologics, Inc.) - P/E Multiple|P/E Multiple Aptevo|Price to Earnings Ratio AIM (AIM ImmunoTech Inc.)|aditxt.com - Price to Earnings Multiple|P/E Multiple GRI (GRI Bio)|P/E Multiple XORTX Therapeutics Inc XRTX|ReShape Lifesciences - P/E Multiple|REVB: Price to Earnings Ratio|INDP (Indaptus Therapeutics) - Price to Earnings Ratio|SCNI (scinai.com) - Price to Earnings Ratio|Price to Earnings Ratio CALI|Price to Earnings Multiple AFMD (Affimed Therapeutics)|Price to Earnings Ratio Allakos Inc. (ALLK)|HOOK: Market Cap to Net Income|P/E Multiple IGMS (IGM Biosciences)|Company Value to Net Income ITOS|Ocean Biomedical - P/E Multiple|TCBP - P/E Multiple|Third Harmonic Bio, Inc (THRD) - Price to Earnings Ratio
